DEFA14A: Relmada Therapeutics Announces 2024 Annual Meeting and Proxy Materials

Relmada Therapeutics has scheduled its 2024 Annual Meeting for May 24, 2024, and is providing proxy materials to stockholders.

Summary

• Relmada Therapeutics, Inc. is holding its Annual Meeting on May 24, 2024.
• Stockholders are encouraged to vote on proposals outlined in the proxy materials.
• The meeting will be held virtually.
• Key proposals include the election of Class III directors, ratification of Marcum LLP as the independent accounting firm, approval of an amendment to the 2021 Equity Incentive Plan to increase the shares of common stock available for issuance by 4.5 million shares, and an advisory vote on executive compensation.
• Stockholders can access proxy materials and vote online at www.ProxyVote.com.

Sentiment

Score: 7

Explanation: The document is a routine announcement of an annual meeting and proxy materials, indicating a neutral to slightly positive sentiment as it reflects standard corporate governance practices.

Positives

• Stockholders have multiple options to access proxy materials and vote, including online, by phone, and by email.
• The company is providing stockholders with the opportunity to vote on important matters related to the company's governance and compensation.

Future Outlook

The document outlines the agenda for the upcoming annual meeting and seeks stockholder approval on key governance and compensation matters.

Industry Context

This announcement is a standard part of corporate governance, ensuring shareholders have the opportunity to participate in key decisions.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• The outcome of the votes can influence the company's direction and executive compensation.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on May 24, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Voting, Relmada Therapeutics, Equity Incentive Plan, Executive Compensation, Directors, Marcum LLP, Shares